Related Experiment Video
Updated: Jun 9, 2026
08:12
Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
[Interventional, intramyocardial stem cell therapy in ischemic cardiomyopathy: update 2010]
M W Bergmann1, K Jaquet, C Schneider
1Klinik für Kardiologie, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, Hamburg, Germany. docbergmann@mac.com
Herz
|September 4, 2010
Summary
Intramyocardial stem cell therapy using NOGA-guided injections is safe and feasible for ischemic cardiomyopathy. Ongoing trials will determine if this regenerative medicine approach becomes a standard cardiac treatment.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Therapy
Context:
- Ischemic cardiomyopathy treatment remains a challenge.
- Autologous bone marrow cell therapy shows safety but limited efficacy.
- Direct myocardial injection offers a potential improvement strategy.
Purpose:
- To evaluate the safety and feasibility of NOGA-guided intramyocardial stem cell therapy.
- To assess the potential of this technique in treating ischemic cardiomyopathy.
- To summarize current evidence and ongoing research in NOGA-guided cardiac cell therapy.
Summary:
- The NOGA method, utilizing CARTO technology, creates a 3D map of the left ventricle for precise cell delivery.
- Studies since 2002 indicate safety, feasibility, and potential effectiveness of NOGA-guided therapy.
- Current data support the hypothesis but await larger multicenter trials for definitive proof.
Impact:
- NOGA-guided stem cell therapy shows promise as a safe and feasible option for acute and chronic ischemic cardiomyopathy.
- Further clinical trials are crucial to establish this approach as a standard cardiac cell therapy.
- Advancements in interventional cardiology and regenerative medicine.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...